MEDICAL DEVICES GLOBAL {MDG}

 Top Mergers & Acquisitions

Natus Medical announced today that it has entered into a definitive agreement that Archimed will receive for a total share value of $ 1.2 billion.

Natus stockholders will receive $ 33.50 in cash for each common stock of the company they own. The transaction is expected to close in the third quarter of 2022 and is subject to customary closing conditions and approval by Natus shareholders and regulatory approvals. According to Natus, once the acquisition is completed, it will no longer be listed on the public market.

Acutus Medical (NSDQ: AFIB) has announced that it has entered into a definitive agreement to sell Medtronic's left heart access portfolio (NYSE: MDT) for $ 50 million.

Medtronic will provide a $ 50 million cash advance to Acutus Medical, Princeton, NJ, upon initial termination of the transaction, subject to standard closing conditions, including the expiration or early termination of all applicable antitrust waiting periods. The agreement is also subject to Acutus' debt refinancing and contingent payment over time based on the achievement of certain milestones and future sales, according to the company.

Acutus Medical's portfolio of callous accessories includes a range of AcQCross septum crimping devices compatible with the housing, an integrated crimping device and AcQGuide Mini housing, an AcQGuide Flex controllable insertion with transseptal dilator and needle, and an AcQGuide Vue controllable housing.

Halozyme Therapeutics (Nasdaq: HALO) has announced that it will acquire Antares Pharma (Nasdaq: ATRS) for an estimated

$960 million.

The boards of both companies approved the transaction and provided Halozyme Antares

$ 5.60 per share in cash.

Conmed (NSDQ: CNMD) has announced that it will take over In2Bones Global for more than $ 145 million after announcing first-quarter results that hit the general consensus on Wall Street. Conmed expects revenue for fiscal 2022 to be in the range of $ 1.105 billion to $ 1.150 billion, up from $ 1.075 billion and $ 1.125 billion, respectively. He expects revised earnings per share in the range of $ 3.50 to $ 3.65.

The company plans to acquire In2Bones Global High Limb Equipment Manufacturer for $ 145 million at the close - and up to another $ 110 million in revenue-based growth over a four-year period. Complaints are subject to customary conditions, including US regulatory approvals. Conmed told the SEC that he expects estimated revenues of $ 20 million in the second half of the year related to the acquisition of In2Bones.